Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration

American Journal of Psychiatry

Volumn 154, Issue 1, 1997, Pages 25-30

  Elrod, Rachael ^b   Peskind, Elaine R ^a   DiGiacomo, Lillian ^b   Brodkin, Kayla I ^b   Veith, Richard C ^b   Raskind, Murray A ^b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; LOCUS CERULEUS; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MENTAL HEALTH; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOENZYMATIC ASSAY; RATING SCALE; STATISTICAL ANALYSIS;

EID: 0031032291     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.1.25     Document Type: Article

References (49)

1. Raskind MA: Alzheimer's disease: treatment of noncognitivc behavioral abnormalities, in Psychopharmacology: The Fourth Generation of Progress. Edited by Kupfer DJ, Bloom FE. New York, Raven Press, 1995, pp 1427-1435
2. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Sehmeidler J, Davis KL: A pilot study of oral physosrigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7:98-104
3. Weiler PG, Mungas D, Bernick C: Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988; 1:226-230
4. Raskind MA, Peskind ER, Halter JB, Jimerson DC: Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry 1984; 4:343-346
5. Bondareff W, Mountjoy CQ, Roth M: Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982; 32:164-168
6. Mann DMA, Lincoln J, Yates PO, Stamp JE, Toper S: Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry 1980; 136:533-541
7. Tomlinson BE, Irving D, Blessed G: Cell loss in the locus coeruleus in senile dementia of the Alzheimer type. J Comp Neurol 1979; 38:490-497
8. Bondareff W, Mountjoy CQ: Number of neurons in nucleus locus ceruleus in demented and non-demented patients: rapid estimation and correlated parameters. Neurobiol Aging 1986; 7: 297-300
9. Tohgi H, Ueno T, Takahashi S, Nozaki Y: Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger's type. J Neural Transm Park Dis Dement Sect 1992; 4:69-77
10. Lawlor BA, Bierer LM, Ryan TM, Schmeidler J, Knott PJ, Williams LL, Mohs RC, Davis KL: Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biol Psychiatry 1995; 38:185-188
11. Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, Nappi G: Cerebrospinal fluid norepinephrine, plasma 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J Neural Transm 1992; 4:191-205
12. Ziegler MC, Lake RC, Wood JH, Ebert MH: Norepinephrine in cerebrospinal fluid: basic studies, effects of drugs and disease, in Neurobiology of Cerebrospinal Fluid. Edited by Wood JH. New York, Plenum, 1980, pp 141-158
13. Weil-Malherbe H, Axelrod J, Tomchick R: Blood brain barrier for adrenaline. Science 1989; 12:1226-1227
14. Peskind ER, Raskind MA, Wilkinson CW, Flatness DE, Halter JB: Peripheral sympathectomy and adrenal medullectomy do not alter cerebrospinal fluid norepinephrine. Brain Res 1986; 367: 258-264
15. Mamalaki E, Brady LS, Goldstein D, Herkenham M: Origins of norepinephrine in rat cerebrospinal fluid. Society for Neuroscience Abstracts 1988; 14:1074
16. Barnhart RL, van Belle G, Edland SD, Kukull W, Borson S, Raskind M, Teri L, McLean P, Larson E: Geographically overlapping Alzheimer's disease registries: comparisons and implications. J Geriatr Psychiatry Neurol 1995; 8:203-208
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
18. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
19. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI: A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991
20. Ziegler MG, Wood JH, Lake CR, Kopin IJ: Norepinephrine and 3-methoxy-4-hydroxyphenyl glycol gradients in human cerebrospinal fluid. Am J Psychiatry 1977; 134:565-568
21. Evans MI, Halter JB, Porte D Jr: Comparison of double- and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma. Clin Chem 1978; 24:567-570
22. Kopin IJ, Gordon EK, Jimerson DC, Polinksy RG: Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 1983; 219:73-75
23. Raskind MA, Peskind ER, Veith RC, Beard JC, Gumbrecht G, Halter JB: Increased plasma and cerebrospinal fluid norepinephrine in older men: differential suppression by clonidine. J Clin Endocrinol Metab 1988; 66:438-443
24. Vijayashankar N, Brody H: A quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J Comp Neurol 1979; 38:490-497
25. Manaye KF, McIntire DD, Mann DMA, German DC: Locus coeruleus cell loss in the aging human brain: a non-random process. J Comp Neurol 1995; 358:79-87
26. Loughlin SE, Foote SL, Fallen JH: Locus coeruleus projections to cortex: topography, morphology and collateralization. Brain Res Bull 1982; 9:287-294
27. Gottfries C-G, Adolfsson R, Aquilonius S-M, Carlsson A, Eckernas S-A, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B: Biochemical changes in dementia disorders of Alzhcimer type (AD/SDAT). Neurobiol Aging 1983; 4:261-271
28. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM: Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res 1987; 401:231-238
29. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH: Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987; 22: 229-246
30. Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, Kopp U: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48:619-624
31. Zubenko GS, Moossy J: Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47:209-214
32. Reifler BV, Larson E, Hanley R: Coexistence of cognitive impairment and depression in geriatric outpatients. Am J Psychiatry 1982; 139:623-626
33. Nakamura S, Sakaguchi T: Development and plasticity of the locus coeruleus: a review of recent physiological and pharmacological experimentation. Prog Neurobiol 1990; 34:505-526
34. Acheson AL, Zigmund MJ: Short and long term changes in tyrosine hydroxylase activity in rat brain after substantial destruction of central noradrenergic neurons. J Neurosci 1981; 1:439-504
35. Unnerstall JR, Long MM: Induction of tyrosine hydroxylase mRNA in locus coeruleus neurons following 6-hydroxydopamine treatment in young and old Fisher 344 rats. Society for Neuroscience Abstracts 1993; 19:456
36. Fritschy JM, Grzanna R: Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol 1992; 321:421-441
37. Madison R, Davis JN: Sprouting of noradrenergic fibers in hippocampus after medial septal lesions: contributions of the central and peripheral nervous systems. Exp Neurol 1983; 80:167-177
38. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR: Alzheimer's disease: loss of neurons in the basal forebrain. Science 1982; 215:1237-1239
39. Featherstone JA, Veith RC, Flatness D, Murburg MM, Villacres EC, Halter JB: Age and alpha-adrenergic regulation of plasma norepinephrine kinetics in humans. J Gerontol 1987; 42:271-276
40. 3H-noradrenaIine released from the mouse hypothalamus. Naunyn Schmiedebergs Arch Pharmacol 1978; 302:337-339
41. 3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol Aging 1991; 12:131-136
42. Peskind ER, Wingerson D, Murray S, Pascualy M, Dobie DJ, Le Corre P, Le Verge R, Veith RC, Raskind MA: Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 1995; 52:774-782
43. Supiano MA, Linares OA, Smith MJ, Halter JB: Age-related differences in norepinephrine kinetics: effect of posture and sodium-restricted diet. Am J Physiol 1990; 259(3, part 1):E422-E431
44. Vitiello B, Veith RC, Molchan SE, Martinez RA, Lawlor BA, Radcliffe J, Hill JL, Sunderland T: Autonomic dysfunction in patients with dementia of the Alzheimer's type. Biol Psychiatry 1993; 34:428-433
45. Holmberg G, Gershon S: Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia 1961; 2:93-106
46. Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR: Adrenergic receptors in aging and Alzheimer's disease: increased β2-receptors in prefrontal cortex and hippocampus. J Neurochem 1989; 53:1772-1781
47. Yudofsky S, Williams D, Gorman J: Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 1981; 138:218-220
48. Nielson KA, Shankle WR, Cotman CW: Neurobiological correlates of aggression and agitation in dementia provide bases for effective treatment: a study of propranolol. Society for Neuroscience Abstracts 1993; 19:400
49. Zubenko GS: Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 1992; 6:77-94